Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration (nAMD)

Core Insights - Roche announced five-year efficacy, safety, and durability data for Susvimo® (ranibizumab injection) in treating neovascular age-related macular degeneration (nAMD), showing sustained treatment effects with approximately 95% of patients requiring no supplemental treatment before each refill [1][2][7] Group 1: Study Results - The Phase III Portal study demonstrated that Susvimo maintained vision and retinal drying over five years, with best-corrected visual acuity (BCVA) showing a decline from 74.4 letters at baseline to 67.6 letters at five years in the Susvimo cohort, and from 76.3 letters to 68.6 letters in the IVT-Susvimo cohort [3][4] - Average central subfield thickness (CST) remained stable, with a reduction of 1.0 µm in the Susvimo cohort and 10.3 µm in the IVT-Susvimo cohort [3] Group 2: Treatment Comparison - Susvimo provides continuous delivery of ranibizumab via a refillable eye implant, contrasting with other treatments that may require monthly injections [5][10] - The Portal study cohort is the largest group of nAMD patients followed prospectively for five years, enhancing the reliability of the results [4][6] Group 3: Clinical Implications - The long-term results support Susvimo's potential to preserve vision in nAMD patients, addressing the challenges of frequent injections associated with traditional anti-VEGF treatments [2][7] - The study's findings may lead to improved real-world clinical outcomes for patients with nAMD, as continuous delivery could offer better vision preservation compared to standard treatments [2][6]